A Phase 2 interventional study of Atrasentan in Nephropathy and Diabetes, sponsored by AbbVie. Completed at 13 sites in 4 countries. Open to male participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-05-07.
Sponsored by AbbVie · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 416 studies in Kidney Diseases with a site in United States — 64 open to participants now, 93 under way, 15 of them phase 3. Kidney Diseases · United States.
Among the 416 studies in Kidney Diseases with a site in United States, this one is the 237th largest by enrollment of the 318 interventional ones that give a count, is one of 18 that started in 2015, is one of 67 in phase 2, and was the 188th registered.
970 studies on the registry are indexed under Kidney Diseases; 184 are open to participants now.
Browse Kidney Diseases studies →64 of the 416 studies in Kidney Diseases with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
Geisinger Clinic · Sites in United States
Ages 18+
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 18–115
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Novartis Pharmaceuticals · Sites in United States, China, Colombia and 5 more countries
Ages 2–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 130 Kidney Diseases studies recruiting now, 76 (58%) set no upper age limit and 34 (26%) stop at 75 or younger; 26 take children under 18; 22 take healthy volunteers.
This study: 30 Years to 75 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
416 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 70 · Phase 2 87 · Phase 3 63 · Phase 4 24
First in 1976; this study’s year is marked. 18 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 64 across 647 interventional studies indexed under Kidney Diseases.
Median enrollment 50 across the 318 interventional studies, 226 across the 93 observational. Of the 295 that completed or were terminated, 126 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
166 of 416 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 5 studies filed under Kidney Diseases — fewer than ten, so there is no comparison to draw.
27 of the studies in Kidney Diseases with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT06087835Phase 3AstraZenecaStudy to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | 2027-02-18 |
| NCT05696613Phase 3Cerium Pharmaceuticals, Inc.A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy | 2027-04-01 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT05153967Vanderbilt University Medical CenterCooperative Assessment of Late Effects for SCD Curative Therapies | 2026-11 |
Add all 27 to your calendar (.ics) → With an account.
Among the 416 studies in Kidney Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the effects of Atrasentan on sperm production and testicular function in male subjects with Type 1 or 2 Diabetes and Nephropathy.
This study included 2 periods: a Treatment Period (up to 26 weeks) followed by an Observational Period (up to an additional 52 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Atrasentan 0.75 mg administered orally once daily (QD) for 26 weeks
Drug: Atrasentan
Atrasentan
Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26
Percentage of Subjects with a Sperm Concentration \< 15 million per mL by Treatment Week 26. Sperm concentration was calculated as measure of the number sperm per milliliter of semen. Duplicate semen samples were collected. The average of the 2 samples were used as the value for that scheduled collection period.
Time frame: Up to 26 weeks
Percentage of Participants Who Entered the Observation Period and Did Not Return to Within 15% of Baseline Sperm Concentration or Above During the 52-Week Observational Period
The percentage of participants who entered the Observational Period and did not return to within 15% of Baseline sperm concentration or above during the 52-week Observational Period. Duplicate semen samples were to be collected during the Observational Period. Sperm concentration was calculated as measure of the number sperm per milliliter of semen. Duplicate semen samples were collected. The average of the 2 samples were used as the value for that scheduled collection period.
Time frame: Up to 52 weeks after the Treatment Period
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Concentration
Duplicate semen samples will be collected during the Treatment and Observational Periods. The average of the 2 samples were used as the value for that scheduled collection period. A negative change from baseline indicated a decrease in sperm concentration.
Time frame: From Week 0 up to Treatment Period Week 26 and Observation Period Week 52
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Motility
Duplicate semen samples will be collected during the Treatment and Observation Periods. The average of the 2 samples were used as the value for that scheduled collection period. A negative change from baseline indicated a lower sperm motility (worsening).
Time frame: From Week 0 up to Treatment Period Week 26 and Observation Observation Week 52
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Morphology
Duplicate semen samples will be collected during the Treatment and Observational Periods. The percentage of sperm with normal versus abnormal morphology will be determined via microscopic analysis. A positive change from baseline indicates an improved sperm morphology.
Time frame: From Week 0 up to Treatment Period Week 26 and Observation Period Week 52
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Semen Volume
Duplicate semen samples will be collected during the Treatment and Observation Periods. The average of the 2 samples were used as the value for that scheduled collection period. A negative change from baseline indicated a decrease in semen volume.
Time frame: From Week 0 to up to Treatment Period Week 26 and Observation Period Week 52
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Serum Testosterone
Serum hormones levels will be tested during the Treatment and Observational Periods. A negative change from baseline indicated a decrease in serum testosterone.
Time frame: From Week 0 up to Treatment Period Week 26 and Observation Period Week 52
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Estradiol
Serum hormones levels were tested during the Treatment and Observational Periods. A negative change from baseline indicated a decrease in serum estradiol.
Time frame: From Week 0 up to Treatment Period Week 26 and Observation Period Week 52
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Lutenizing Hormone (LH)
Serum hormones levels will be tested during the Treatment and Observational Periods. A positive change from baseline indicated an increase in serum lutenizing hormone.
Time frame: From Week 0 to up to Treatment Period Week 26 and Observation Period Week 52
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in in Follicle Stimulating Hormone (FSH)
Serum hormones levels will be tested during the Treatment and Observational Periods. A positive change from baseline indicated an increase in serum follicle stimulating hormone.
Time frame: From Week 0 to Treatment Week 26 and Observation Week 52
Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Inhibin B
Serum hormones levels will be tested during the Treatment and Observational Periods. A negative change from baseline indicated a decrease in serum Inhibin B.
Time frame: From Week 0 up to Treatment Period Week 26 and Observation Period Week 52
| Milestone | Atrasentan |
|---|---|
| Started | 20 |
| Completed | 17 |
| Not completed | 3 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Protocol violation | 1 |
Percentage of Subjects with a Sperm Concentration \< 15 million per mL by Treatment Week 26. Sperm concentration was calculated as measure of the number sperm per milliliter of semen. Duplicate semen samples were collected. The average of the 2 samples were used as the value for that scheduled collection period.
| percentage of participants | Atrasentan |
|---|---|
| Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26 | 23.5 |
The percentage of participants who entered the Observational Period and did not return to within 15% of Baseline sperm concentration or above during the 52-week Observational Period. Duplicate semen samples were to be collected during the Observational Period. Sperm concentration was calculated as measure of the number sperm per milliliter of semen. Duplicate semen samples were collected. The average of the 2 samples were used as the value for that scheduled collection period.
| percentage of participants | Atrasentan |
|---|---|
| Percentage of Participants Who Entered the Observation Period and Did Not Return to Within 15% of Baseline Sperm Concentration or Above During the 52-Week Observational Period | 11.8 |
Duplicate semen samples will be collected during the Treatment and Observational Periods. The average of the 2 samples were used as the value for that scheduled collection period. A negative change from baseline indicated a decrease in sperm concentration.
| sperm * million per milliliter(X10^6/mL) | Atrasentan |
|---|---|
| Treatment Period Week 13 | 2.2 ± 42.21 |
| Treatment Period Week 26 | -10.6 ± 53.44 |
| Observation Period Week 13 | 35.8 ± 113.60 |
| Observation Period Week 26 | -16.5 ± 0.00 |
| Observation Period Week 39 | -27.5 ± 19.09 |
| Observation Period Week 52 | -25.8 ± 1.06 |
Duplicate semen samples will be collected during the Treatment and Observation Periods. The average of the 2 samples were used as the value for that scheduled collection period. A negative change from baseline indicated a lower sperm motility (worsening).
| percent motility | Atrasentan |
|---|---|
| Treatment Period Week 13 | -5.8 ± 13.65 |
| Treatment Period Week 26 | -7.4 ± 15.77 |
| Observation Period Week 13 | -0.3 ± 19.20 |
| Observation Period Week 26 | -6.3 ± 5.30 |
| Observation Period Week 39 | 10.8 ± 15.20 |
| Observation Period Week 52 | 1.8 ± 16.62 |
Duplicate semen samples will be collected during the Treatment and Observational Periods. The percentage of sperm with normal versus abnormal morphology will be determined via microscopic analysis. A positive change from baseline indicates an improved sperm morphology.
| percentage of normal | Atrasentan |
|---|---|
| Treatment Period Week 13 | -1.1 ± 4.78 |
| Treatment Period Week 26 | -2.2 ± 7.54 |
| Observation Period Week 13 | -0.8 ± 7.53 |
| Observation Period Week 26 | -6.8 ± 0.35 |
| Observation Period Week 39 | -2.3 ± 1.77 |
| Observation Period Week 52 | 1.8 ± 0.35 |
Duplicate semen samples will be collected during the Treatment and Observation Periods. The average of the 2 samples were used as the value for that scheduled collection period. A negative change from baseline indicated a decrease in semen volume.
| milliliter (mL) | Atrasentan |
|---|---|
| Treatment Period Week 13 | 0.0 ± 0.65 |
| Treatment Period Week 26 | -0.3 ± 0.75 |
| Observation Period Week 13 | 0.0 ± 1.39 |
| Observation Period Week 26 | 0.0 ± 0.35 |
| Observation Period Week 39 | 0.1 ± 0.42 |
| Observation Period Week 52 | -0.4 ± 0.14 |
Serum hormones levels will be tested during the Treatment and Observational Periods. A negative change from baseline indicated a decrease in serum testosterone.
| nanomole/liter (nmol/L) | Atrasentan |
|---|---|
| Treatment Period Week 13 | 0.2 ± 2.18 |
| Treatment Period Week 26 | 0.8 ± 2.33 |
| Observation Period Week 13 | 0.6 ± 2.08 |
| Observation Period Week 26 | -0.3 ± 0.85 |
| Observation Period Week 39 | -1.6 ± 1.37 |
| Observation Period Week 52 | -1.1 ± 1.68 |
Serum hormones levels were tested during the Treatment and Observational Periods. A negative change from baseline indicated a decrease in serum estradiol.
| Picomoles Per Litre (pmol/L) | Atrasentan |
|---|---|
| Treatment Period Week 13 | -11.7 ± 44.57 |
| Treatment Period Week 26 | -18.6 ± 42.04 |
| Observation Period Week 13 | -17.8 ± 62.78 |
| Observation Period Week 26 | -47.3 ± 39.97 |
| Observation Period Week 39 | 20.3 ± 4.78 |
| Observation Period Week 52 | 10.5 ± 45.54 |
Serum hormones levels will be tested during the Treatment and Observational Periods. A positive change from baseline indicated an increase in serum lutenizing hormone.
| International Units/Liter (IU/L) | Atrasentan |
|---|---|
| Treatment Period Week 13 | 1.0 ± 2.60 |
| Treatment Period Week 26 | 0.7 ± 2.44 |
| Observation Period Week 13 | 1.3 ± 1.33 |
| Observation Period Week 26 | 1.9 ± 2.35 |
| Observation Period Week 39 | 0.5 ± 0.07 |
| Observation Period Week 52 | 1.8 ± 3.46 |
Serum hormones levels will be tested during the Treatment and Observational Periods. A positive change from baseline indicated an increase in serum follicle stimulating hormone.
| International Units/Liter (IU/L) | Atrasentan |
|---|---|
| Treatment Period Week 13 | 1.1 ± 2.43 |
| Treatment Period Week 26 | 0.8 ± 1.91 |
| Observation Period Week 13 | 0.4 ± 1.60 |
| Observation Period Week 26 | 0.7 ± 1.49 |
| Observation Period Week 39 | 0.4 ± 1.57 |
| Observation Period Week 52 | 0.8 ± 0.59 |
Serum hormones levels will be tested during the Treatment and Observational Periods. A negative change from baseline indicated a decrease in serum Inhibin B.
| picogram per milliliter (pg/mL) | Atrasentan |
|---|---|
| Treatment Period Week 13 | -2.7 ± 24.19 |
| Treatment Period Week 26 | -8.8 ± 34.73 |
| Observation Period Week 13 | -7.2 ± 20.77 |
| Observation Period Week 26 | -22.7 ± 27.10 |
| Observation Period Week 39 | -21.0 ± 16.97 |
| Observation Period Week 52 | -5.5 ± 2.12 |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 30 days after the last dose of study drug (up to approximately 30 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atrasentan | 0/20 (0%) | 3/20 (15%) | 12/20 (60%) |
| Event | Atrasentan |
|---|---|
| DIABETIC KETOACIDOSISMetabolism and nutrition disorders | 2/20 |
| CARDIOGENIC SHOCKCardiac disorders | 1/20 |
| OSTEOMYELITISInfections and infestations | 1/20 |
| POSTOPERATIVE RESPIRATORY FAILUREInjury, poisoning and procedural complications | 1/20 |
| RESPIRATORY DISTRESSRespiratory, thoracic and mediastinal disorders | 1/20 |
| RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 1/20 |
| AORTIC DISSECTIONVascular disorders | 1/20 |
| Event | Atrasentan |
|---|---|
| OEDEMA PERIPHERALGeneral disorders | 4/20 |
| NASOPHARYNGITISInfections and infestations | 4/20 |
| DIARRHOEAGastrointestinal disorders | 2/20 |
| NON-CARDIAC CHEST PAINGeneral disorders | 2/20 |
| HEADACHENervous system disorders | 2/20 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 2/20 |
| ANAEMIABlood and lymphatic system disorders | 1/20 |
| HAEMORRHAGIC ANAEMIABlood and lymphatic system disorders | 1/20 |
| ANGINA PECTORISCardiac disorders | 1/20 |
| LEFT VENTRICULAR HYPERTROPHYCardiac disorders | 1/20 |
Safety Analysis Set
| Age, Continuous(years) | Atrasentan |
|---|---|
| Mean | 55.1 ± 12.94 |
| Sex: Female, Male(Participants) | Atrasentan |
|---|---|
| Female | 0 |
| Male | 20 |
| Ethnicity (NIH/OMB)(Participants) | Atrasentan |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Atrasentan |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 15 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Apr 2015 to primary completion in Apr 2018, 36 months.
Results were first posted in May 2019, 1 year after primary completion.
Of 41 phase 2 interventional studies under Kidney Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 36 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atrasentan